First-in-human phase I study of TQ-B3139 (CT-711) in advanced non-small cell lung cancer patients with ALK and ROS1 rearrangements

Yuxiang Ma, Hongyun Zhao,Jinhui Xue,Li Liu,Nong Yang, Yang Zhang,Haiyan Yang,Shaodong Hong,Yi Xiong, Zhonghan Zhang,Liang Zeng, Hui Pan,Chunhua Zhou,Yongchang Zhang, Xunqiang Wang, Xi Han, Xiaojing Wan,Yang Shao,Jingwen Liu,Yunpeng Yang

European Journal of Cancer（2022）

引用 4|浏览12

暂无评分

摘要

•TQ-B3139 is a novel second generation ALK-TKI, also inhibiting ROS and c-Met.•TQ-B3139 has promising antitumor activity and tolerated toxicity.•Favorable intracranial ORR and PFS were observed in ALK + NSCLC patients.•Variant3 and TP53 alteration were associated with poor PFS in TKI-treated patients.

查看译文

关键词

TQ-B3139,ALK rearrangement,Efficacy,Safety,Next-generation sequencing

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要